Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997310 | 0.81 | GAA (0.62) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL23145996 | 0.81 | ALDH1A1 (0.54) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL579287 | 0.81 | GAA (0.61) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL7621847 | 0.80 | ALDH1A1 (0.75) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL4061712 | 0.80 | TSHR (0.68) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL6701189 | 0.79 | MEN1 (0.62) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL8230173 | 0.79 | GAA (0.58) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL30529012 | 0.76 | MEN1 (0.55) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL20788433 | 0.76 | MEN1 (0.55) | GAAMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL3193135 | 0.76 | SIGMAR1 (0.62) | GAAMEN1KMT2AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | GAA 2061/4885MEN1 3704/4885KMT2A 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.